Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mega scale-up of nanotechnology research budget mulled

This article was originally published in The Gold Sheet

Executive Summary

FDA could certainly use the additional $25 million per year for nanotechnology research that Sen. Mark Pryor, D-Ark., has proposed to authorize for the next five years, Commissioner Margaret Hamburg told the Senate Appropriations Committee March 9. Hamburg was there to defend the agency's fiscal year 2011 budget request, which includes $7 million for nanotechnology-related regulatory science activities. Much of the additional research the senator from Arkansas proposed would take place at the agency's National Center for Toxicological Research in Jefferson, Ark. When Pryor asked if FDA could spend the extra $25 million wisely, Hamburg assured him that it's a "very, very important emerging technology" and that "we always have to evolve our capabilities as emerging technologies also evolve" (see "The Pink Sheet," March 15, 2010

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel